Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class...

{
  "signal_id": "101b7021-24c3-55c1-922e-71e857c1225e",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-02T15:20:00+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/02/3373899/0/en/biogen-s-litifilimab-demonstrates-rapid-and-durable-efficacy-in-new-52-week-phase-2-data-from-ongoing-phase-2-3-amethyst-study-reinforcing-its-potential-as-a-first-in-class-therapy.html",
    "title": "Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus",
    "excerpt": "CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated results, presented at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria, represent the longest dataset reported for litifilimab in CLE and further support its potential to achieve rapid and durable improvements in skin disease activity. In the study, participants treated with litifilimab in the double-blind, placebo-controlled period showed continued clinical improvements in skin disease activity through Week 52. Notably, participants who switched from placebo to litifilimab treatment at Week 24 experienced a rapid onset of treatment effect as early as four weeks.",
    "product": "litifilimab",
    "summary": "Biogen announced 52-week results from the Phase 2 part of its ongoing AMETHYST Phase 2/3 study for litifilimab, a potential first-in-class therapy for cutaneous lupus erythematosus (CLE), showing rapid and durable efficacy.",
    "location": "Cambridge, Massachusetts, USA",
    "planning": true,
    "confidence": 0.9,
    "product_data": {
      "name": "litifilimab",
      "full_text": "litifilimab in people living with cutaneous lupus erythematosus (CLE)",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-10-02T15:20:00Z",
    "location_data": [
      {
        "city": "Cambridge",
        "state": "Massachusetts",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-02",
    "article_sentence": "Biogen Inc. (Nasdaq: BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE)."
  }
}

curl https://signals.autobound.ai/v1/signals/101b7021-24c3-55c1-922e-71e857c1225e \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"biogen.com","limit":20}'